Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?
The primary therapy for patients with chronic hepatitis C virus (HCV) infection is interferon alfa. However, use of interferon for treatment of chronic HCV has several shortcomings that limit its effectiveness. Interferon has a very short half-life, must be administered multiple times weekly, and is associated with significant side effects. "PEGylation" is a process whereby the inert polymer, polyethylene glycol (PEG), is attached to a protein pharmaceutical. This process has been shown to alter the properties of PEGylated proteins in a manner that significantly extends half-life, reduces immunogenicity, and enhances biologic activity when compared with the native protein. In recent years, several PEGylated forms of interferon alfa have been developed. Recent studies have demonstrated that PEG-interferons have a significantly prolonged half-life and sustained virologic response when compared with standard interferon. Studies to evaluate the effects of combining PEG-interferons with ribavirin are currently underway. The role PEG-interferons will play in patients who have either relapsed or failed to respond to previous interferon or interferon/ribavirin therapy remains to be defined.
Shiffman
M L
ML
Hepatology Section, Medical College of Virginia Commonwealth University, Box 980341, Richmond, VA 23298, USA. mshiffma@hsc.vcu.edu
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007668:Kidney / Q000378:metabolism; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a